VivoSeq
Other

Urinary Urgency

2

Pipeline Programs

0

Active Trials

1

Companies Involved

Urinary urgency is an early-stage landscape with 2 programs across 1 company. The most active players are Astellas. 1 therapy is approved.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs

Trial Status

2

clinical trials

Completed2 · 100%

Trial Activity

Mirabegron and Urinary Urgency Incontinence
Completed·LLoyola University·Phase 4·NCT02495389·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)